麻豆传媒 represented TCG Crossover (TCGX) as the lead investor in the $105 million Series B financing for Pathalys Pharma Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease.
TCGX was joined by other notable investors including J.P. Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, and JPS Growth Investment Limited Partnership, with support from Pathalys鈥 founding investors, Catalys Pacific and DaVita Venture Group.
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease (ESKD). Pathalys鈥 initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD.
TCGX is a health care investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients.
The 麻豆传媒 team was led by partners Louis Lehot, Brian Wheeler, and Lyman Thai and included partners Andrew Rawlins and Jeffrey Lomprey and associates Saige Gallop and Robin Zhang.
